Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06073353
Other study ID # 23-332
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date March 31, 2025

Study information

Verified date February 2024
Source Massachusetts General Hospital
Contact Areej El-Jawahri, MD
Phone 617-724-4000
Email ael-jawahri@mgb.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial aims to evaluate whether a psychosocial mobile application (THRIVE-M), is efficacious for improving quality of life, psychological distress, and fatigue in patients living with multiple myeloma compared to usual care.


Description:

Multiple myeloma, the second most common hematologic malignancy, can be associated with severe end-organ destruction and life-threatening complications (e.g., kidney failure, infection, anemia) resulting in significant morbidity (e.g., pain syndromes, fatigue). The protracted course and treatment of multiple myeloma is also characterized by physical symptoms that can undermine psychological well-being, functioning, and quality of life across the illness trajectory and care continuum. Despite the high psychological burden that may accompany life with multiple myeloma, the special mental health workforce needed to adequately address their psychological needs is limited. Hence, mobile application-delivered psychosocial interventions offer an innovative approach to overcome the shortage of psychosocial services to support the unique needs of patients living with multiple myeloma. With no psychosocial mobile application interventions for patients living with multiple myeloma, we developed a patient-centered, population-specific, mobile-application psychosocial intervention, THRIVE-M, tailored to the unique needs of patients living with multiple myeloma. With this study, we will establish the impact of THRIVE-M on patient-reported outcomes compared to usual care. The study will use validated questionnaires to measure patients' quality of life, psychological distress symptoms, fatigue, and self-management targets like coping, spiritual well-being, and self-efficacy. Study questionnaires will be completed in the hospital or clinic, with an option to also complete them remotely via a secure web link or a mailed paper copy. Divine Mercy University is funding this research study.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (aged 18 years or older) with one of the following diagnoses: 1. newly diagnosed multiple myeloma receiving first-line therapy, 2. multiple myeloma on maintenance therapy, or 3. relapsed multiple myeloma receiving 2nd or 3rd line therapy - Ability to comprehend, read, and respond to questions in English Exclusion Criteria: - Patients with acute or unstable psychiatric or cognitive conditions that the treating clinicians believe prohibit informed consent or compliance with study procedures

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
THRIVE-M
THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules: Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms Relationships module - helping patients articulate different support needs and communication styles in navigating relationships emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose. Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Coping based on the Measure of Current Status Part A (MOCS-A) scale Compare coping between participants receiving THRIVE-M versus usual care as measured by the Measure of Current Status Part A (MOCS-A). The MOCS-A ranges from 0-52 with higher scores indicating greater coping skills.
Higher scores on the MOCS-A (range 0-52) indicate better coping.
Up to 15 weeks
Other Self-efficacy based on the Cancer Self-Efficacy Scale (CASE) Compare self-efficacy between participants receiving THRIVE-M versus usual care as measured by the Cancer self-efficacy Scale (CASE). The Case ranges from 0-170 with higher scores indicating higher self-efficacy.
Higher scores on the CASE (range 0-170) indicate greater self-efficacy.
Up to 15 weeks
Other Spiritual Well-being based on the FACT-spiritual scale Compare spiritual well-being between participants receiving THRIVE-M versus usual care as measured by the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp-12). The FACIT-SP-12 score ranges from 0-48 with higher scores indicating better spiritual wellbeing.
Higher scores on the FACIT-Sp-12 (range 0-48) indicate greater spiritual well-being.
Up to 15 weeks
Other Optimism based on the Life Orientation Test-Revised (LOT-R) scale Compare optimism between participants receiving THRIVE-M versus usual care as measured by the Life Orientation Test-Revised (LOT-R). The score range is 0-24 with higher scores indicating better optimism
Higher scores on the LOT-R (range 0-24) indicate greater optimism.
Up to 15 weeks
Other Life Satisfaction based on the Satisfaction with Life Scale (SWLS) Compare life satisfaction between participants receiving THRIVE-M versus usual care as measured by the Satisfaction with Life Scale (SWLS). The SWLS ranges 5-25 with higher scores indicating better life satisfaction.
Higher scores on the SWLS (range 5-35) indicate greater life satisfaction.
Up to 15 weeks
Other Positive Affect based on the Positive Affect Schedule (PANAS) Compare positive affect between participants receiving THRIVE-M versus usual care as measured by the positive affect subscale of the Positive Affect Schedule (PANAS). The score ranges 10-50, with higher scores indicating more positive affect.
Higher scores on the positive affect scale of the PANAS (range 10-50) indicate greater positive affect.
Up to 15 weeks
Other Gratitude based on the Gratitude Questionniare-6 Compare gratitude between participants receiving THRIVE-M versus usual care as measured by the Gratitude Questionnaire-6 (GQ-6). the score range 6-42 with higher scores indicating more gratitude.
Higher scores on the GQ-6 (range 6-42) indicate greater gratitude.
Up to 15 weeks
Other Loneliness based on the Cancer Loneliness Scale (CLS) Compare loneliness between participants receiving THRIVE-M versus usual care as measured by the Cancer Loneliness Scale (CLS). The score ranges 20-80 with higher scores indicating greater feelings of loneliness
Higher scores on the CLS (range 15-75) indicate greater loneliness.
Up to 15 weeks
Other Usability of THRIVE-M app based on the System Usability Scale We will use the System Usability Scale to assess the usability of THRIVE-M for those receiving the intervention. This scale ranes 0-100 with higher scores indicating better usability.
Higher scores on the System Usability Scale ( range 0-100) indicate better usability.
Up to 8 weeks
Primary Quality of Life as measured by the Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) scale Compare quality of life between participants receiving THRIVE-M versus usual care as measured by the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) at 8 weeks. the FACT-MM score ranges 0-164 with higher scores indicating better quality of life
Higher scores on the FACT-MM (range 0-164) indicate better quality of life.
8 weeks
Secondary Quality of life longitudinally based on the FACT-MM scale Compare quality of life using the Functional Assessment of Cancer therapy (FACT-MM) between the two groups. The FACT-MM ranges 0-164 with higher scores indicating better quality of life.
Higher scores on the HADS anxiety subscale (range 0-21) indicate greater anxiety symptoms.
Up to 15 weeks
Secondary Anxiety Symptoms based on the Hospital Anxiety and Depression Scale Compare anxiety symptoms between participants receiving THRIVE-M versus usual care as measured by the Hospital Anxiety and Depression Scale (HADS)-anxiety subscale. The HADS-Anxiety subscale ranges from 0-21 with higher scores indicating worse anxiety symptoms.
Higher scores on the HADS anxiety subscale (range 0-21) indicate greater anxiety symptoms.
Up to 15 weeks
Secondary Depression Symptoms based on the Hospital Anxiety and Depression Scale Compare depression symptoms between participants receiving THRIVE-M versus usual care as measured by the Hospital Anxiety and Depression Scale (HADS)-depression. The HADS-Depression subscale ranges from 0-21 with higher scores indicating worse depression symptoms.
Higher scores on the HADS-depression subscale (range 0-21) indicate greater depression symptoms.
Up to 15 weeks
Secondary Post-traumatic Stress Disorder (PTSD) Symptoms based on the PTSD Checkist Compare PTSD symptoms between participants receiving THRIVE-M versus usual care as measured by the PTSD Checklist-Civilian Version. The PTSD checklist score ranges from 17-85 with higher scores indicating worse post-traumatic stress symptoms.
Higher Scores on the PTSD Checklist-Civilian Version (range 17-85) indicate greater PTSD symptoms.
Up to 15 weeks
Secondary Fatigue based on the FACT-Fatigue Scale Compare fatigue between participants receiving THRIVE-M versus usual care as measured by the Functional Assessment of Cancer Therapy-Fatigue (FACT-Fatigue). The FACT-Fatigue ranges from 0-52 with higher scores indicating lower fatigue.
Higher scores on the FACT-Fatigue (range 0-52) indicate worse fatigue.
Up to 15 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1